Translation of evidence into pain management practices in acute care environments. This project addresses the urgent need to reduce the substantial pain experienced by patients following surgery by improving the clinical processes associated with the treatment of pain. Each year in Australia, six million people are admitted to hospital for surgery. A recent review of Australian research has shown that up to 40% of hospitalised surgical patients experience significant pain. Despite the availabili ....Translation of evidence into pain management practices in acute care environments. This project addresses the urgent need to reduce the substantial pain experienced by patients following surgery by improving the clinical processes associated with the treatment of pain. Each year in Australia, six million people are admitted to hospital for surgery. A recent review of Australian research has shown that up to 40% of hospitalised surgical patients experience significant pain. Despite the availability of effective treatment, pain after surgery is often under-treated and is one of the main postoperative adverse outcomes. A consequence of poor pain management is that patients experience unnecessary suffering, higher incidence of postoperative complications significant risk of developing chronic post-surgical pain.Read moreRead less
Drug Companies, their Patenting Strategies and High-Cost Pharmaceuticals: An Empirical Investigation. Pharmaceuticals are a vital part of clinical services that maintain and improve Australia's health; they are also costly, absorbing a substantial proportion of the national health expenditures. By conferring market protections, the patent system helps the manufacturers of pharmaceuticals to recoup the high costs of research associated with developing new products. Abuses of the patent system by ....Drug Companies, their Patenting Strategies and High-Cost Pharmaceuticals: An Empirical Investigation. Pharmaceuticals are a vital part of clinical services that maintain and improve Australia's health; they are also costly, absorbing a substantial proportion of the national health expenditures. By conferring market protections, the patent system helps the manufacturers of pharmaceuticals to recoup the high costs of research associated with developing new products. Abuses of the patent system by pharmaceutical manufacturers have the potential to stifle competition and inappropriately raise the costs of pharmaceuticals to society. This innovative, cross-disciplinary, research will investigate the existence of abusive patents and, if necessary, propose reforms that will prevent further abuse and reduce the size of the health budget. Read moreRead less
Improvement of anthracycline chemotherapy by enhancement of apoptotic responses and tumour targeted activation. Improved outcomes for anthracycline anticancer chemotherapy is of clear benefit to the nation. Tumour-localised treatment is expected to lead to improved responses, reduced side-effects and improved quality of life while rational selection of drug combinations is expected to enable treatment of tumours that were previously resistant to anthracyclines. With an aging population in Austra ....Improvement of anthracycline chemotherapy by enhancement of apoptotic responses and tumour targeted activation. Improved outcomes for anthracycline anticancer chemotherapy is of clear benefit to the nation. Tumour-localised treatment is expected to lead to improved responses, reduced side-effects and improved quality of life while rational selection of drug combinations is expected to enable treatment of tumours that were previously resistant to anthracyclines. With an aging population in Australia the incidence of cancer is predicted to rise dramatically - improved treatment outcomes and better use of chemotherapeutics will be of obvious national benefit. The development of new tumour-targeted agents is the subject of joint Intellectual Property between Australia and the USA, offering potential economic benefit. Read moreRead less
Tumour localisation and enhancement of anthracycline anticancer activity. The anthracyclines are one of the most widely used anticancer agents today. If the cytotoxicity of these agents can be localised to tumour cells, or their activity improved, then this will result in improved response rates, less side-effects and an improved quality of life for many patients for whom anthracycline treatment is an important part of their therapy. This will result in enormous national/community benefit to an ....Tumour localisation and enhancement of anthracycline anticancer activity. The anthracyclines are one of the most widely used anticancer agents today. If the cytotoxicity of these agents can be localised to tumour cells, or their activity improved, then this will result in improved response rates, less side-effects and an improved quality of life for many patients for whom anthracycline treatment is an important part of their therapy. This will result in enormous national/community benefit to an aging Australian population that is becoming increasingly more prone to cancer. Read moreRead less
Anticancer drug development: Enhancing the anticancer activity of mitoxantrone. Many cancer sufferers may benefit from this work if we are able to develop more active derivatives of mitoxantrone, or develop procedures to inhibit the repair of DNA lesions induced by mitoxantrone. This may result in therapies with improved response, reduced drug dosage and/or reduced side-effects. Because this work may result in one or more patents, and possibly commercialisation with Australian (and overseas) pha ....Anticancer drug development: Enhancing the anticancer activity of mitoxantrone. Many cancer sufferers may benefit from this work if we are able to develop more active derivatives of mitoxantrone, or develop procedures to inhibit the repair of DNA lesions induced by mitoxantrone. This may result in therapies with improved response, reduced drug dosage and/or reduced side-effects. Because this work may result in one or more patents, and possibly commercialisation with Australian (and overseas) pharmaceutical companies, there are potential commercial benefits to Australia. The "discovery" aspect of this work may also identify other cellular responses to mitoxantrone (ie specific genes which are re-expressed) and this may also reveal new targets to further enhance the activity of this drug.Read moreRead less
Molecular basis for the synergistic potentiation of anthracycline anticancer agents by formaldehyde-releasing prodrugs. AIMS: The overall aim is to develop a full understanding of the molecular basis for the synergistic activation of Adriamycin (and other anthracycline anticancer agents) by formaldehyde-releasing prodrugs such as AN-9.
SIGNIFICANCE: Because Adriamycin is currently one of the most widely used anticancer agents, and this activity has the potential to be dramatically enhanced by t ....Molecular basis for the synergistic potentiation of anthracycline anticancer agents by formaldehyde-releasing prodrugs. AIMS: The overall aim is to develop a full understanding of the molecular basis for the synergistic activation of Adriamycin (and other anthracycline anticancer agents) by formaldehyde-releasing prodrugs such as AN-9.
SIGNIFICANCE: Because Adriamycin is currently one of the most widely used anticancer agents, and this activity has the potential to be dramatically enhanced by the concurrent use of formaldehyde-releasing prodrugs, a biochemical understanding of these processes will provide the basis to exploit this synergy to provide improved treatment outcomes (eg, lower drug doses,reduced side-effects, improved activity against drug-resistanct tumours etc).
EXPECTED OUTCOMES: The long-term outcome of this project is commercialisation to develop products for clinical use based on this synergy (eg, drug/prodrug combinations) and ultimately the development of tumour-directed therapy to yield a tumour-localised anticancer response.Read moreRead less
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE0668246
Funder
Australian Research Council
Funding Amount
$400,000.00
Summary
Advanced Cell Labelling and Imaging Facility. Understanding the genetic regulation of cellular processes such as migration, differentiation and growth is an important frontier technology with significant biomedical potential. The Australian community is facing an increasing need to provide solutions for a variety of human diseases and disorders, including birth defects, nervous system injury and stroke, and ageing-related conditions. The proposed facility will allow researchers to test in vivo g ....Advanced Cell Labelling and Imaging Facility. Understanding the genetic regulation of cellular processes such as migration, differentiation and growth is an important frontier technology with significant biomedical potential. The Australian community is facing an increasing need to provide solutions for a variety of human diseases and disorders, including birth defects, nervous system injury and stroke, and ageing-related conditions. The proposed facility will allow researchers to test in vivo gene/pharmaceutical therapies as well as to better understand the genetic regulation of normal cellular processes. Read moreRead less
Understanding the cardioprotective effects of flavonols. Heart attack and stroke are a major cause of death and disablement in Australia. Current therapies do not treat the underlying causes of these diseases. In this project we will investigate a promising new drug treatment for these diseases and will determine how this poorly understood drug acts to reduce damage to the heart. This project will lead to new treatments for cardiovascular diseases and will enhance our understanding of the causes ....Understanding the cardioprotective effects of flavonols. Heart attack and stroke are a major cause of death and disablement in Australia. Current therapies do not treat the underlying causes of these diseases. In this project we will investigate a promising new drug treatment for these diseases and will determine how this poorly understood drug acts to reduce damage to the heart. This project will lead to new treatments for cardiovascular diseases and will enhance our understanding of the causes of these disease states.Read moreRead less
Towards safe care and consumer engagement: addressing the complexities of communication processes for managing medications in hospitals. Ineffective communication is the most common cause of medication problems in Australia. This study focuses on how health professionals of various disciplines including medicine, pharmacy and nursing communicate with each other about medications. Integral involvement of consumers and family members will ensure that health and social outcomes are considered from ....Towards safe care and consumer engagement: addressing the complexities of communication processes for managing medications in hospitals. Ineffective communication is the most common cause of medication problems in Australia. This study focuses on how health professionals of various disciplines including medicine, pharmacy and nursing communicate with each other about medications. Integral involvement of consumers and family members will ensure that health and social outcomes are considered from different perspectives, which are therefore likely to be successful. Examination of communication processes will help lead to safe care and consumer involvement. The unique knowledge obtained will inform policies in various clinical settings and identify strategies for better communication. Health professionals and consumers can adopt these strategies to improve medication safety. Read moreRead less
Development of computer-based decision support tools using population pharmacokinetic/pharmacodynamic models. Diabetes is an epidemic that presents an enormous burden to health systems of both developed and developing nations. Australia spends an estimated $35 billion on the condition annually, with costs set to rise with increasing diagnosis rates. Additionally, the burden of diabetes is more prominent in indigenous Australians. We intend to improve management of this disease in non-indigenous ....Development of computer-based decision support tools using population pharmacokinetic/pharmacodynamic models. Diabetes is an epidemic that presents an enormous burden to health systems of both developed and developing nations. Australia spends an estimated $35 billion on the condition annually, with costs set to rise with increasing diagnosis rates. Additionally, the burden of diabetes is more prominent in indigenous Australians. We intend to improve management of this disease in non-indigenous and indigenous Australians by development of a user-friendly computer-based decision support tool for doctors. Once established, this tool will have applications in other fields of health care where support is needed to make informed dosing decisions for critical medications and have the potential to reduce financial and social impacts of chronic disease.Read moreRead less